

# Accepted Manuscript

Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center

Keshavamurthy Vinay, MD, DNB, Simone Cazzaniga, MD, Kyle T. Amber, MD, Laurence Feldmeyer, MD, PhD, Luigi Naldi, MD, Luca Borradori, MD



PII: S0190-9622(17)32689-0

DOI: [10.1016/j.jaad.2017.11.024](https://doi.org/10.1016/j.jaad.2017.11.024)

Reference: YMJD 12127

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 12 August 2017

Revised Date: 31 October 2017

Accepted Date: 5 November 2017

Please cite this article as: Vinay K, Cazzaniga S, Amber KT, Feldmeyer L, Naldi L, Borradori L, Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center, *Journal of the American Academy of Dermatology* (2017), doi: 10.1016/j.jaad.2017.11.024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-**  
2 **term outcomes in a single center**

3 *Running head: First line rituximab in pemphigus*

4 Keshavamurthy Vinay MD, DNB,<sup>1,2</sup> Simone Cazzaniga MD,<sup>1,3</sup> Kyle T. Amber MD,<sup>4</sup>  
5 Laurence Feldmeyer MD, PhD,<sup>1</sup> Luigi Naldi MD,<sup>1,3,4</sup> Luca Borradori MD<sup>1</sup>

6  
7 <sup>1</sup> Department of Dermatology, Inselspital, Bern University Hospital, University of  
8 Bern, Bern, Switzerland

9 <sup>2</sup> Department of Dermatology, Venereology and Leprology, Postgraduate Institute of  
10 Medical Education and Research, Chandigarh, India-160012

11 <sup>3</sup> Centro Studi GISED, Bergamo, Italy

12 <sup>4</sup> Department of Dermatology, San Bortolo Hospital, Vicenza, Italy

13 <sup>5</sup> Department of Dermatology, University of California Irvine Health, Irvine, CA,  
14 USA.

15 **Correspondence and reprint request:**

16 Dr. Keshavamurthy Vinay

17 Department of Dermatology, Inselspital, Bern University Hospital, Switzerland

18 Email: vinay.keshavmurthy@gmail.com

19

20 Word count: 594

21 Table count: 2

22 No of references: 5

23 Funding source: The study was supported by the International society of Dermatology

24 Mentorship grant provided to K.V. L.B. is supported by Swiss National Science

25 Foundation (grant number 310030E-171664; FOR 2497\_PEGASUS\_TP7)

26 Conflict of interest: None

27 IRB status: Approved

28 **Keywords:** Complete remission; First line; Pemphigus; Relapse; Rituximab

29

30

Download English Version:

<https://daneshyari.com/en/article/8715162>

Download Persian Version:

<https://daneshyari.com/article/8715162>

[Daneshyari.com](https://daneshyari.com)